WHWKHealthcare · BiotechnologyWHWK Stock Forecast: Whitehawk Therapeutics, Inc. Price Predictions for 2026-2027
The 8 Wall Street analysts covering Whitehawk Therapeutics, Inc. hold a median 12-month price target of $7.5 — +89.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 65 of 100 as at 1 Aug 2026 — in the upper half.
WHWK stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores Whitehawk Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (88): The shares have been drifting up relative to others.
Growth (16): Sales and profits are flat, shrinking, or growing more slowly than they were.
The rank is the raw material. Whether the rules would actually own Whitehawk Therapeutics, Inc. — and when they’d sell — is the membership.
WHWK stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on WHWK, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +89.4% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 13 July 2026 | Leerink Partners | Initiates | Outperform | $9.00 |
| 25 June 2026 | B. Riley Securities | Initiates | Buy | — |
| 16 Apr 2026 | Citizens | Initiates | Market Outperform | — |
| 22 Dec 2025 | Jones Trading | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
WHWK analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Whitehawk Therapeutics, Inc. (WHWK) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- 11.7×
- Price / sales
- 26.6×
- Price / book
- 1.6×
- EV / EBITDA
- −0.5×
Cheaper than 56% of US stocks
Cheaper than 8% of US stocks
Cheaper than 54% of US stocks
Cheaper than 65% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- −288.3%
- Net margin
- 89.4%
Higher than 10% of US stocks
Higher than 99% of US stocks
- Return on equity
- −68.5%
- Return on assets
- −42.5%
- Dividend yield
- —
Higher than 17% of US stocks
Higher than 9% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
WHWK vs competitors
The nearest names by industry and size, scored by the same model — like for like.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. WHWK appears on the weeks it earns a place.
Frequently asked questions about WHWK stock
What is the WHWK stock price forecast for 2026-2027?
The 8 Wall Street analysts covering Whitehawk Therapeutics, Inc. have a median 12-month price target of $7.5, with estimates ranging from $4 to $10. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is WHWK stock a buy right now?
Of the 8 analysts covering Whitehawk Therapeutics, Inc., 5 rate it a Buy, 3 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Whitehawk Therapeutics, Inc. 65 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank WHWK?
As at 1 Aug 2026, Whitehawk Therapeutics, Inc. ranks 65 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (88 of 100).
Will WHWK stock go up?
No one can know that. What the data says: the median 12-month target from 8 analysts implies +89.4% from the last close, and Ticker Nerd's factor model ranks Whitehawk Therapeutics, Inc. 65 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the WHWK stock forecast for 2030?
No analyst covering Whitehawk Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for WHWK are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $4 to $10 over the next 12 months.
How has WHWK stock performed over the past year?
Whitehawk Therapeutics, Inc. returned +127.6% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Whitehawk Therapeutics, Inc. do?
Whitehawk Therapeutics, Inc. is an oncology biotechnology company focused on the discovery and development of antibody-drug conjugate (ADC) therapies for cancer.
About Whitehawk Therapeutics, Inc.
Whitehawk Therapeutics, Inc. is an oncology biotechnology company focused on the discovery and development of antibody-drug conjugate (ADC) therapies for cancer. The company’s primary objective is to leverage next-generation ADC platform technologies—engineered for greater stability and a higher therapeutic index—to address the needs of patients with challenging, treatment-resistant tumors. Its pipeline comprises three ADC assets, each designed to target clinically validated proteins that are broadly expressed across various tumor types, with a strategic emphasis on lung and gynecological cancers. Whitehawk Therapeutics employs advanced tumor biology insights to more effectively dose and deliver their therapies, aiming to overcome limitations found in earlier ADC approaches. Formerly operating under the name Aadi Bioscience, the company relaunched with a sharpened focus in March 2025, reflecting its commitment to innovation in cancer treatment. Headquartered in Morristown, New Jersey, Whitehawk Therapeutics occupies a significant niche within the healthcare and biotechnology sectors, serving as a key player in the advancement of targeted cancer therapies for patients with significant unmet medical needs.
CEO Dr. David J. Lennon Ph.D. · 29 employees · United States · https://ir.whitehawktx.com